research use only
Cat.No.S8426
| Related Targets | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase |
|---|---|
| Other Myc Inhibitors | MYCi975 10058-F4 MYCi361 EN4 APTO-253 Mycro 3 Cpd. 37 ML327 MYCMI-6 BTYNB |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| Daudi cells | Cytotoxicity assay | 3 to 5 days | Cytotoxicity against human Daudi cells assessed as growth inhibition after 3 to 5 days by MTT assay, IC50=10 Μm | |||
| HL60 cells | Cytotoxicity assay | 3 to 5 days | Cytotoxicity against human HL60 cells assessed as growth inhibition after 3 to 5 days by MTT assay, IC50=30 μM | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 66 mg/mL
(198.6 mM)
Ethanol : 8 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 332.31 | Formula | C18H12N4O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 413611-93-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC=C(C=C1)C2=CC=CC=C2NC3=CC=C(C4=NON=C34)[N+](=O)[O-] | ||
| Targets/IC50/Ki |
c-Myc
(Cell-free assay) 2.8 μM(Kd)
|
|---|---|
| In vitro |
10074-G5 binds to and distorts the bHLH-ZIP domain of c-Myc, thereby inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity. In vitro, this compound inhibits the growth of Daudi Burkitt's lymphoma cells and disrupts c-Myc/Max dimerization. Daudi cells accumulates this chemical, and the highest intracellular concentration is observed at 6 h. It inhibits c-Myc/Max dimerization in Daudi cells by approximately 75% at 4 h, and this inhibition is maintained through 24 h of incubation. Total c-Myc protein expression also decreases, and after 24 h exposure to 10 μM of this compound, c-Myc protein expression decreases approximately 40% compared with vehicle-treated control. It is cytotoxic in vitro against Daudi and HL-60 cells, which overexpress c-Myc .
|
| In vivo |
The plasma half-life of 10074-G5 in mice treated with 20 mg/kg i.v. is 37 min, and peak plasma concentration is 58 μM, which is 10-fold higher than peak tumor concentration. The lack of antitumor activity probably is caused by the rapid metabolism of this compound to inactive metabolites, resulting in tumor concentrations of this chemical insufficient to inhibit c-Myc/Max dimerization. Plasma peak concentration (Cmax) of 58.5 ± 2.7 nmol/ml is observed at 5 min after intravenous administration of 20 mg/kg to mice bearing Daudi xenografts, its concentration in plasma declines rapidly. Except for lung, liver, and fat, tissue concentrations of this compound are lower than those of plasma at all time points.
|
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | MYCN HER2 / p-AKT / AKT / HOXB7 |
|
24859015 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.